copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Home | Harrow, Inc. Harrow is redefining the standard of care in eyecare with a portfolio of trusted, high-value pharmaceutical solutions that deliver proven safety, efficacy, and affordability
Careers | Harrow, Inc. At Harrow, our values aren’t just guiding words—they shape how we grow, innovate, and work together Humility, ownership, preparedness, and entrepreneurship create the foundation for a culture where initiative is celebrated, creativity thrives, and impact is real
Corporate Presentation November 2025 - harrow. com Harrow was founded to advance the standard of eye care and deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes
Harrow Announces Closing of Acquisition of Melt Pharmaceuticals Integration into Harrow: Melt Pharmaceuticals will be fully integrated into Harrow’s operations to ensure a seamless transition and accelerate progress toward NDA submission, approval, and market launch
Harrow To Report Third Quarter 2025 Financial Results After Market . . . The Company will also post its third quarter Letter to Stockholders to the “Investors” section of its website, harrow com Harrow will host a conference call and live webcast at 8:00 a m Eastern Time on Tuesday, November 11, 2025, to discuss the results and provide a business update
0001493152-23-008718 | 10-K | Harrow, Inc. Document Details Form 10-K Filing Date March 23, 2023 Document Date December 31, 2022 Form Description Annual report which provides a comprehensive overview of the company for the past year Filing Group Annual Filings Company Harrow, Inc Issuer
Harrow Completes Transfer of the TRIESENCE® New Drug Application In January of 2023, Harrow agreed to acquire the U S commercial rights to TRIESENCE Aside from the transfer of the TRIESENCE NDA ahead of the date previously agreed to, all other acquisition terms remain unchanged
Form 8-K for Harrow INC filed 10 06 2025 Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes For more information about Harrow, please visit harrow com